Navigation Links
Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
Date:1/27/2010

BANGALORE, India, January 27 /PRNewswire-FirstCall/ -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development said: "We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."

"We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo Pharmaceuticals. "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."

About Jubilant Biosys

Jubilant Biosys Ltd. (JBL) (www.jubilantbiosys.com), a subsidiary of Jubilant Organosys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

About Jubilant Organosys Limited

Jubilant Organosys Ltd., headquartered at Noida, an integrated pharmaceutical industry player, is India's largest Custom Research and Manufacturing Services company (CRAMS) and a leading Drug Discovery and Development Solution Provider. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, and Health Care. The Company also manufactures Industrial and Performance products. http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For Business Queries
    Kailash Swarna
    Sr. VP and COO,
    Jubilant Drug Discovery and Development
    kailash_swarna@jubilantbiosys.com

    For Media
    Seema Ahuja
    VP-Corporate Marketing & Communications
    Jubilant Organosys Ltd
    +919810631779,
    seema_ahuja@jubl.com

SOURCE Jubilant Biosys Ltd


'/>"/>
SOURCE Jubilant Biosys Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
9. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, ... single-cell sequencing during the American Association for Cancer Research ... Center in Washington, D.C. , April ... gene expression of thousands of cells at the individual ... Experts on-hand at AACR to discuss expanded ...
(Date:3/28/2017)... SACRAMENTO, Calif. , March 28, 2017 /PRNewswire/ ... Officer of international life sciences corporation Anpac ... company set a new, international record, processing and ... proprietary, "Cancer Differentiation Analysis" (CDA) liquid ... in World Nobel Prize Laureate Summit publications, Anpac ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
(Date:3/28/2017)... ... 28, 2017 , ... Executive search firm, Slone Partners, announces ... Harvill is a distinguished life sciences expert with a proven track record in ... a wide range of services related to laboratory testing and analysis for the ...
Breaking Biology Technology:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
Breaking Biology News(10 mins):